INmune Bio Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
1.380
+0.100 (7.81%)
Mar 11, 2026, 3:27 PM EDT - Market open
INmune Bio Revenue
INmune Bio had revenue of $50.00K in the twelve months ending September 30, 2025, up 19.05% year-over-year. In the year 2024, INmune Bio had annual revenue of $14.00K, down -90.97%.
Revenue (ttm)
$50.00K
Revenue Growth
+19.05%
P/S Ratio
680.58
Revenue / Employee
$2,273
Employees
22
Market Cap
36.69M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14.00K | -141.00K | -90.97% |
| Dec 31, 2023 | 155.00K | -219.00K | -58.56% |
| Dec 31, 2022 | 374.00K | 193.00K | 106.63% |
| Dec 31, 2021 | 181.00K | 170.00K | 1,545.45% |
| Dec 31, 2020 | 11.00K | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| NovaBay Pharmaceuticals | 10.30M |
| Pluri | 1.34M |
| Werewolf Therapeutics | 1.14M |
| ABVC BioPharma | 797.92K |
| Outlook Therapeutics | 205.70K |
INMB News
- 12 days ago - INmune Bio Inc. (INMB) Discusses XPro1595 Phase II MINDFuL Results and Registrational Strategy in Alzheimer's Disease Transcript - Seeking Alpha
- 12 days ago - INmune Bio Inc. (INMB) Discusses MissionEB Phase III Trial and CORDStrom as a Disease-Modifying Therapy for RDEB Transcript - Seeking Alpha
- 16 days ago - INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer's Webinar - GlobeNewsWire
- 20 days ago - INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB - GlobeNewsWire
- 4 weeks ago - INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB - GlobeNewsWire
- 6 weeks ago - INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives - GlobeNewsWire
- 3 months ago - Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio's CORDStrom™ Platform - GlobeNewsWire
- 3 months ago - INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595's Evidence Base in High-Inflammation Alzheimer's Patients - GlobeNewsWire